Cobolimab
Cobolimab is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for non-small-cell lung cancer, melanoma and hodgkin lymphoma, with its target not yet stated publicly.
Overview
Cobolimab is an investigational agent whose form is not stated in the registry developed by GlaxoSmithKline. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy), in non-small-cell lung cancer, melanoma, hodgkin lymphoma, glioma & glioblastoma and osteosarcoma. The largest, NCT04655976, plans to enrol 758 participants (actual) with primary completion expected 2025-06-05. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Cobolimab" OR ABSTRACT:"Cobolimab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cobolimab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBA3071
Shares Melanoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJK08
Shares Hepatocellular carcinoma, Melanoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentENV-501
Shares Melanoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentTNG456
Shares Glioma & glioblastoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentIBI363
Shares Melanoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentT3011
Shares Melanoma, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentIDRX-42
Shares GSK and the tags pipeline, ctgov-ingest.
- TreatmentVelzatinib
Shares GSK and the tags pipeline, ctgov-ingest.